Founded in 2024, with a current fund size of 66M USD, we are a prominent life sciences venture capital working closely with industry innovators to create cutting-edge medications and technologies.
Our primary focus is on developing inventive therapeutics that meet unfulfilled medical needs.
We adopt a proactive stance in identifying teams focused on developing impactful treatments, aiding in crafting efficient development strategies to make these therapies accessible to patients.
Moreover, functioning as an open-ended fund, we extend financial support and networking opportunities to enable young biotech scientists to establish and expand their ventures.
By assisting companies in accessing the capital market, our objective is to cultivate a mutually beneficial ecosystem that fosters investment growth, nurtures entrepreneurial successes, and propels the progress of innovative therapeutics.
Yu-Ju Chen
Assistant Vice President, Investment Dept.
Experience
- Management Consultant, Oliver Wyman, USA
- Senior Scientist, Pfizer, USA
- Postdoctoral Researcher, UT Southwestern Medical Center, USA
William Liu
Manager, Finance & Accounting Dept.
Experience
- Senior Team Lead, Finance Dept., Marketech International Corporation
- Specialist, Finance Dept., Chang Chun Petrochemical
- Audit Senior, Deloitte & Touche
Julia Chang
Head of Internal Audit
Experience
- Investment Manager, Grand Fortune Venture Management Corporation
- Special Assistant to General Manager, Aquastone Capital Management Limited
- Senior Manager, Underwriting Dept., Grand Fortune Securities
Nick Huang
Assistant Vice President, Information Technology Dept.
Experience
- Manager, Grand Fortune Venture Management Corporation
- R&D Section Manager, Dynacolor Inc.
Penny Wu
Manager, Administration Dept.
Experience
- Manager, Grand Fortune Venture Management Corporation
- Manager, Direct Investment Dept, Mega Bank
- Assistant Manager, Taiwan Index Plus
If you have any questions or inquiries, please contact us.
Email：ir@beileybiofund.com
